Safety Profile of Innohep Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Tinzaparin sodium (Primary) ; Heparin
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Adverse reactions; Therapeutic Use
Acronyms IRIS
Sponsors LEO Pharma

01 Jul 2011 Results published in Thrombosis Research.
15 Apr 2008 Status changed from recruiting to in progress, reported by ClinicalTrials.gov
01 Aug 2007 The low-molecular weight heparin used in this study has been identified as tinzaparin sodium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com